Black Diamond Therapeutics, Inc. (BDTX)
Company Description
Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers.
The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial.
It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial.
The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018.
Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Country | United States |
Founded | 2014 |
IPO Date | Jan 30, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 54 |
CEO | Dr. Mark A. Velleca M.D., Ph.D. |
Contact Details
Address: One Main Street, 14th Floor Cambridge, Massachusetts 02142 United States | |
Phone | 617-417-5868 |
Website | blackdiamondtherapeutics.com |
Stock Details
Ticker Symbol | BDTX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $19.00 |
CIK Code | 0001701541 |
CUSIP Number | 09203E105 |
ISIN Number | US09203E1055 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Mark A. Velleca M.D., Ph.D. | Chief Executive Officer, President and Chairman |
Dr. David M. Epstein Ph.D. | Co-Founder and Director |
Dr. Fang Ni Pharm.D. | Chief Financial Officer, Principal Financial Officer and Chief Business Officer |
Brent Hatzis-Schoch Esq., J.D. | Chief Operating Officer and General Counsel |
Dr. Elizabeth Buck Ph.D. | Co-Founder and Chief Scientific Officer |
Erika Jones | Vice President of Finance, Corporate Controller and Principal Accounting Officer |
Elizabeth L. Montgomery | Chief People Officer |
Dr. Sergey Yurasov M.D., Ph.D. | Chief Medical Officer |
Melanie Morrison | Chief Development Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 12, 2024 | 10-K | Annual Report |
Mar 12, 2024 | 8-K | Current Report |
Mar 11, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 18, 2024 | 8-K | Current Report |
Jan 4, 2024 | 8-K | Current Report |
Dec 13, 2023 | 8-K | Current Report |
Nov 9, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |